

Mirtazapine Solid Formulation

Version Date of last issue: 30.09.2023 Revision Date: SDS Number: 06.04.2024 50167-00022 Date of first issue: 23.01.2015 5.0

Section 1: Identification

Product identifier Mirtazapine Solid Formulation

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

Manufacturer or supplier's details

Company : Organon & Co.

Address 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone +1-551-430-6000

Emergency telephone number: +1-215-631-6999

E-mail address EHSSTEWARD@organon.com

Section 2: Hazard identification

Classification of the substance or mixture

Reproductive toxicity : Category 2

Specific target organ toxicity - : Category 2 (Nervous system) repeated exposure (Oral)

GHS Label elements, including precautionary statements

Hazard pictograms

Signal word

Hazard statements H361fd Suspected of damaging fertility. Suspected of damag-

ing the unborn child.

H373 May cause damage to organs (Nervous system) through

prolonged or repeated exposure if swallowed.

Precautionary statements Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.



Mirtazapine Solid Formulation

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection/ hearing protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-	85650-52-8	>= 10 -< 20
methylpyrazino[2,1-a]pyrido[2,3-		
c][2]benzazepine		
Starch	9005-25-8	>= 10 -< 20

Section 4: First-aid measures

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging fertility. Suspected of damaging the

unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Protection of first-aiders

Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Silicon oxides

Special protective actions for fire-fighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).



Mirtazapine Solid Formulation



Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

Section 7: Handling and storage

Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation : Use or Advice on safe handling : Do not

Advice on safe handling : Do not breathe dust.
Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.



Mirtazapine Solid Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 50167-00022
 Date of first issue: 23.01.2015

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b- Hexahydro-2- methylpyrazino[2,1- a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 μg/m3	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Starch	9005-25-8	PEL (long term)	10 mg/m3	SG OEL
		TWA	10 mg/m3	ACGIH

Appropriate engineering control measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear the following personal protective equipment:

Safety goggles

Skin protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not

, ,





Version 5.0

Revision Date: 06.04.2024

SDS Number: 50167-00022

Date of last issue: 30.09.2023 Date of first issue: 23.01.2015

determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Section 9: Physical and chemical properties

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature

: No data available

Mirtazapine Solid Formulation



Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

products

Oxidizing agents

No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of :

exposure

Inhalation
Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: mammalian cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: mammalian cells



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Rat

Cell type: Bone marrow Application Route: Oral Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Mouse Application Route : Oral

Exposure time : 18 month(s)

LOAEL : 200 mg/kg body weight

Result : equivocal Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 20 mg/kg body weight

Result : equivocal Target Organs : Liver, Thyroid

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 15 mg/kg body weight

Symptoms: Effect on estrous cycle, Increase of early resorp-

tions

Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were

detected.

Effects on foetal develop- : Test Type: Development

ment Species: Rat

Application Route: Oral



Mirtazapine Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 50167-00022
 Date of first issue: 23.01.2015

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected., No teratogenic effects

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 40 mg/kg body weight Result: No adverse effects, No teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experi-

ments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Exposure routes : Ingestion

Target Organs : Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Rat
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species: DogLOAEL: 15 mg/kgApplication Route: OralExposure time: 52 WeeksTarget Organs: Nervous system

Symptoms : Tremors

Species : Dog
LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 13 Weeks



Mirtazapine Solid Formulation

Date of last issue: 30.09.2023 Version Revision Date: SDS Number: 06.04.2024 50167-00022 Date of first issue: 23.01.2015 5.0

Target Organs Nervous system, Testis

Symptoms **Tremors**

Starch:

Species Rat

NOAEL >= 2,000 mg/kgApplication Route : Skin contact Exposure time : 28 Days

Method : OECD Test Guideline 410

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Ingestion Symptoms: Drowsiness, constipation, dry mouth, asthenia,

Dizziness, Disorientation

Section 12: Ecological information

Toxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l

> Exposure time: 96 h Method: FDA 4.11

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 19.5 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7

mq/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2

mq/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l

Exposure time: 31 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

NOEC (Daphnia magna (Water flea)): 0.32 mg/l

Exposure time: 21 d



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

ic toxicity) Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

No data available

Bioaccumulative potential

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)

Bioconcentration factor (BCF): 334 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 2.78

Mobility in soil

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environ-

mental compartments

: log Koc: 4.48

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

UN number : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
UN proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen-

ger aircraft)

Not applicable

IMDG-Code

UN number Not applicable UN proper shipping name Not applicable Not applicable Class Subsidiary risk Not applicable Packing group Not applicable Not applicable Labels **EmS Code** Not applicable Not applicable Marine pollutant

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazard-

Environmental Protection and Management (Haz

ous Substances) Regulations

Not applicable

Fire Safety (Petroleum and Flammable Materials)

Regulations

: Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

Mirtazapine Solid Formulation



Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 06.04.2024

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

SG OEL : Singapore. Workplace Safety and Health (General Provisions)

Regulations - First Schedule Permissible Exposure Limits of

Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Tem-



Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 50167-00022 Date of first issue: 23.01.2015

perature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN